Objectives: Head and neck cancer (HNC) diagnosis through the 2-week wait, urgent suspicion of cancer (USOC) pathway has failed to increase early cancer detection rates in the UK. A head and neck cancer risk calculator (HaNC-RC) has previously been designed to aid referral of high-risk patients to USOC clinics (predictive power: 77%). Our aim was to refine the HaNC-RC to increase its prediction potential. Design: Following sample size calculation, prospective data collection and statistical analysis of referral criteria and outcomes. Setting: Large tertiary care cancer centre in Scotland. Participants: 3531 new patients seen in routine, urgent and USOC head and neck (HaN) clinics. Main outcome measures: Data collected were as follows: demographics, social history, presenting symptoms and signs and HNC diagnosis. Univariate and multivariate regression analysis were performed to identify significant predictors of HNC. Internal validation was performed using 1000 sample bootstrapping to estimate model diagnostics included the area under the receiver operator curve (AUC), sensitivity and specificity.
| INTRODUC TI ON
The cancer treatment outcomes in the UK have been persistently lower than many countries in Europe as has been highlighted in the EUROCARE cancer studies. 1, 2 It has been suggested that this may be due to the delays in cancer detection, with patients presenting in advanced cancer stages. 3 Head and neck cancer (HNC) is the 8th most common cancer in the UK with a continuing rise in its incidence. 4 Previous audits from England and Ireland showed that the majority of cancers are diagnosed at a disease stage III or IV. 4, 5 21% of HNC patients visited their GP more than twice prior to being diagnosed with cancer. 6 In the recent years, there has been a drive for the development of risk calculators designed to identify cancer at early stages. This is an area of great opportunity for improvement of patients' cancer journeys from initial presentation in primary care, to diagnosis in the hospital setting and initiation of treatment. 7 At present, several risk calculators are available for common cancers, such as prostate, lung or ovarian cancer, which have been externally validated and are recommended for use to aid prompt referral of high-risk individuals to specialist clinics for further assessment. 8 However, most of these normograms require results of blood tests and radiological findingsin addition to patients' symptoms and demographics-to calculate cancer probability, which potentially limits their widespread adoption in the primary care settings. 9 On the other hand, there are also examples where risk can be established solely on the basis of symptoms and demographics, such as for lung and colorectal cancer. [10] [11] [12] Risk calculators do not only have the potential to contribute to earlier diagnosis of cancers but could also lead to service delivery improvements. Only 35%-38% of HNC in the UK are currently diagnosed via the 2-week wait pathway, with the rest of cases identified in other types of outpatient appointments or emergency admissions. 13 With an average of 100 000 HNC urgent suspicion of cancer (USOC) referrals annually in the UK 14 and an annual HNC incidence of 12 000, 4 one can extrapolate a UK-wide USOC HNC conversion rate of 4.3%. A review of the literature has highlighted a large number of inappropriate USOC referrals and an average HNC diagnosis of only 8%. 15, 16 The above underline the importance of early HNC diagnosis and the need for change of the current referral pathways. Although cancer risk calculators have been available for the last 10-20 years for other common cancers, prediction models for HNC have only recently started to emerge. The first head and neck cancer risk calculator (HaNC-RC) in 2016 based on patients' symptoms, signs and demographics using data from 4715 patients seen in USOC clinics from Birmingham and Newcastle (area under the receiver operator characteristic curve [AUC]: 0.77; sensitivity: 74.8%, specificity: 65.9%). 16 The variables included in the model are available in Table 1 .
It was subsequently externally validated with a cohort from a different UK region (Glasgow), yielding an AUC of 0.81, combined with high sensitivity (79.3%) and specificity (68.6%). 17 Another calculator was proposed by a different research group, applying an alternative symptom combination, demographics as well as smoking and alcohol data based on a cohort of 1075 USOC referrals (Table 1) . Although the AUC was high at 0.79, the sensitivity was low at 31% with high false negative figures in their external validation cohort. 18 Artificial intelligence methods have also been attempted for the development of HNC risk calculators with the variation logistic regression being suggested the most effective method. 19 (Table 1) .
Current trends in this area lean towards validation of existing normograms, combined with continuous improvement through further iterations for increased predictive power instead of continuous generation of new prediction models. 20 The aim of this study was therefore to attempt to further increase the predictive power of the HaNC-RC by assessing the potential for inclusion of other significant symptoms (such as weight loss, neck pain and sore throat), the refinement of symptoms already in the model (addition of symptom laterality and persistency) and the addition of social history factors (smoking, alcohol). • HaNC-RC v.2 has a higher predictive power; sensitivity and specificity compared with its previous version.
| ME THODS
• It is envisaged that the HaNC-RC v2 will be used to effectively triage patients to routine, urgent and USOC clinics to reduce cancer waiting times and increase HNC diagnosis though the USOC pathway. 
| Statistical analysis
Univariable logistic regression analysis was performed to identify significant variables for potential inclusion in the multivariate analysis. All variables that reached the α = .1 level of significance were screened for potential inclusion including any possible two-way interactions of these variables which met the stricter threshold for off for a USOC referral was selected to be the probability value that generated the highest value combination of sensitivity and specificity simultaneously. Following exclusion of the USOC cases, a second threshold was calculated using the same principle for the rest of the referrals, with those above the recommended cut-off being considered for an urgent (6 weeks) appointment. Chi-square analysis was performed to compare the distribution of HNC diagnosis based on the current GP triaging and the one generated implementing the USOC and urgent thresholds on our data set. For the reclassification of referrals, the true incidence of cases was used; hence, the un-boosted cancer cases were used (n = 230) and
for the calculation of the NPV and PPV based on the USOC cut-off.
AUC, sensitivity and specificity values were also calculated using the previous version of the HaNC-RC for comparisons to the latest version. The R and SPSS statistical software were used for data analysis. The R libraries used for prediction and AUC were as follows: Epi; ROCR; Deducer.
| Ethical considerations
The data reported by the clinicians in the clinical notes did not deviate from standard practice. No ethics committee approval was therefore required for this study. Instead, the project was registered with Caldicott guardian of the NHS Greater Glasgow and Clyde (GGC/07/02/17) as quality improvement project. No patient identifiable information was included in the database. Table 3 .
| RE SULTS
The most common presenting symptom was hoarseness (n = 1124, 31.8%), followed by presence of a neck lump (n = 1103, 31.2%). Patients' demographics, alcohol and smoking status were also significant factors. Table 5 We modelled the potential impact the calculator could have on patient referral. was statistically significant (P < .0001), and this could occur whilst seeing less patients through the USOC and urgent route ( Table 6 ).
An online calculator to measure the HNC probability of a patient presenting with the symptoms and signs of the HaNC-RC v2 is available online at http://orlhe alth.com/risk-calcu lator-2.html. 21
| D ISCUSS I ON

| Synopsis of new findings
Our study increased the predictive power of the previous HaNC-RC (v.1) from 77% 16 
| Comparison with other studies
The new variables included in the HaNC-RC v.2 are supported by previous cohort studies in the USOC referrals in which univariate TA B L E 6 Cancer detection in head and neck clinics with current triage system compared with suggested HaNC-RC v2 triaging (USOC referral: for probability cut-offs ≥0.071, urgent referrals: probability cut-offs 0. analysis was performed to identify significant cancer predictors such as unintentional weight loss, smoking and alcohol. 16, 17 Persistent hoarseness and neck lump have been previously highlighted as the most common symptoms resulting in cancer diagnosis. [16] [17] [18] [19] These symptoms were part of HaNC-RC since its first version. One of the new additions to the HaNC-RC v2 is the sore throat symptom. This is supported by recent studies, showing unilateral sore throat to have a 9.5% positive predictive value in identification of HNC. 22 Indeed, in our multivariate model, patients with unilateral persistent sore throat were 9.7 times more likely to have cancer compared with individuals without sore throat. By making these changes, the predictive power of the revised calculator, following internal validation, was 88.6%. This is substantially higher than the ROC of the HaN-RC v.1 (77%) and the ROC of the Lau et al, model (79%). 16, 18 Our study is the first to include patients from all types of clinic 
| Limitations of the study and future directions
One of the limitations of this study is that the calculator was designed from data collected from only one region in Scotland which could limit the generalisability of the model. Nevertheless, previous study has shown directly comparable demographics, symptoms presentation and cancer detection outcomes between Scottish and English cohorts, making the calculator relevant for use across the UK. 17 Additionally, the HaNc-RC v2 has only been internally validated.
Further work is required on external validation of the HaNC-RC v2, and prospective audits of the possible models are needed to establish the best pathway, detection outcomes and long-term outcomes of patients being triaged using the calculator.
It will be also interesting to investigate whether machine learning techniques can improve further the 88.6% prediction power of the HaNC-RC v2. Nevertheless, our multivariable logistic regression performed better than the best selected machine learning model in the publication by Moore et al, with a sensitivity of 7.7% and a specificity of 25.8% but their selected probability cut-off used was not provided for direct comparisons. 19 We hope that despite these limitations, we have generated the groundwork for further research in the use of a risk calculator for HNC. Beyond further work on validation, we should also consider pathways for clinical implementation of the tool.
| CON CLUS IONS
Improvement of the detection rate of cancer in the HaN clinics is possible with the use of a cancer prediction model. The second version of the head and cancer risk calculator has achieved a very high prediction power using a combination of significant symptoms, patients' demographics and social history factors. With this high prediction power, it has not only significant potential to improve patients' outcomes but also contribute to better allocation of NHS resources by redesigning the running of the head and clinics. External validation of the new version of the tool is required as well as trial of its use as a triaging aid.
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